Comparative Pharmacology
Head-to-head clinical analysis: FYLNETRA versus NEULASTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FYLNETRA versus NEULASTA.
FYLNETRA vs NEULASTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FYLNETRA (filgrastim-ayow) is a granulocyte colony-stimulating factor (G-CSF) analog that binds to the G-CSF receptor on neutrophils and their precursors, stimulating proliferation, differentiation, and functional activation of neutrophils.
Pegfilgrastim is a recombinant methionyl human granulocyte colony-stimulating factor (G-CSF) conjugated to polyethylene glycol. It binds to G-CSF receptors on hematopoietic progenitor cells, stimulating proliferation, differentiation, and release of neutrophils from the bone marrow.
3.6 mg/kg subcutaneously once daily for up to 14 days. Dose based on absolute neutrophil count.
6 mg subcutaneously once per chemotherapy cycle, administered at least 24 hours after cytotoxic chemotherapy and at least 14 days before next cycle.
None Documented
None Documented
Terminal elimination half-life approximately 3.5 hours (range 2–5 hours); supports daily dosing in most patients for myelosuppressive chemotherapy.
Terminal elimination half-life is approximately 15-23 hours (mean ~18 hours) in healthy subjects, allowing for once-per-cycle dosing for chemotherapy-induced neutropenia.
Renal (primarily, as unchanged drug and metabolites, minor biliary/fecal)
Primarily renal clearance (through glomerular filtration and proteolytic degradation). Approximately 80% of the dose is eliminated renally as degraded peptides.
Category C
Category C
Colony-Stimulating Factor
Colony-Stimulating Factor